Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation

• Taysha Gene Therapies outlined an accelerated registration plan for TSHA-102, a one-time intrathecal gene therapy candidate for Rett syndrome.
• REVEAL Part A showed a 100% primary-endpoint response rate in 12 patients, with no treatment-related serious adverse events or dose-limiting toxicities.
• REVEAL pivotal trial dosing completed in 17 females aged 6 to <22 years at 1x10¹⁵ total vector genomes.
• FDA alignment supports a potential BLA filing based on the REVEAL 6-month interim analysis, with Part A data included for comparability.
• ASPIRE dosing completed in 4 females aged 2 to <4 years; at least 3 months of safety data may support a broad age 2+ label.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on August 31, 2026, and is solely responsible for the information contained therein.